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Abstract
Worldwide interest in artificial intelligence (AI) applications is growing rapidly. In medicine, devices based on machine/deep
learning have proliferated, especially for image analysis, presaging new significant challenges for the utility of AI in healthcare.
This inevitably raises numerous legal and ethical questions. In this paper we analyse the state of AI regulation in the context of
medical device development, and strategies to make AI applications safe and useful in the future. We analyse the legal framework
regulating medical devices and data protection in Europe and in the United States, assessing developments that are currently taking
place. The European Union (EU) is reforming these fields with new legislation (General Data Protection Regulation [GDPR],
Cybersecurity Directive, Medical Devices Regulation, In Vitro Diagnostic Medical Device Regulation). This reform is gradual, but
it has now made its first impact, with the GDPR and the Cybersecurity Directive having taken effect in May, 2018. As regards the
United States (U.S.), the regulatory scene is predominantly controlled by the Food and Drug Administration. This paper considers
issues of accountability, both legal and ethical. The processes ofmedical device decision-making are largely unpredictable, therefore
holding the creators accountable for it clearly raises concerns. There is a lot that can be done in order to regulate AI applications. If
this is done properly and timely, the potentiality of AI based technology, in radiology as well as in other fields, will be invaluable.
Teaching Points
• AI applications are medical devices supporting detection/diagnosis, work-flow, cost-effectiveness.
• Regulations for safety, privacy protection, and ethical use of sensitive information are needed.
• EU and U.S. have different approaches for approving and regulating new medical devices.
• EU laws consider cyberattacks, incidents (notification and minimisation), and service continuity.
• U.S. laws ask for opt-in data processing and use as well as for clear consumer consent.
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Abbreviations
CT Computed tomography
EU European Union
FDA Food and drug administration
GDPR General data protection regulation
HIPAA Health insurance portability and accountability act
IVDR In vitro diagnostic medical device regulation
MDR Medical devices regulation
MRI Magnetic resonance imaging
U.S. United States
Introduction
Artificial intelligence (AI) is a branch of computer science
dedicated to the creation of systems that perform tasks that
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usually require human intelligence, with different technical
approaches [1]. The term AI is used to describe computer
systems that mimic cognitive functions, such as learning and
problem-solving [2]. These systems are currently based on
artificial neural networks, which are flexible mathematical
models using multiple algorithms to identify complex nonlin-
ear relationships within large datasets [3], nowadays known as
big data. Huge amounts of information can be retrieved from
electronic archives, which could hardly be analysed, searched,
or interpreted using traditional data-processing methods. Big
data includes data from mobile phone applications, wearable
technology, social media, environmental and lifestyle-related
factors, socio-demographics, omic data (e.g., genomics, meta-
bolomics, proteomics, radiomics), and data from standardised
electronic health records or precision medicine platforms [4].
Among the health data, medical images such as those
obtained through x-ray, computed tomography (CT), mag-
netic resonance imaging (MRI) and ultrasound examina-
tions constitute one of the most interesting types of data,
with high potential for research and clinical applications.
Among other things, these data could help in improving
the automatic detection of diseases (while minimising hu-
man errors) [5], creating study protocols [6], improving
image quality and decreasing radiation dose [7], decreasing
MRI scanner time [8], optimising staffing and scanner
utilisation, thereby reducing costs [9], and offering the pos-
sibility of performing expensive and time-consuming
screening programs in countries that otherwise cannot af-
ford them [10, 11].
Machine learning is a term introduced by Arthur Samuel in
1959 [12] to define a field of AI where computers learn auto-
matically from data accumulation; it has been extensively ap-
plied for big data analysis [13]. Within the machine learning
domain, deep learning has emerged as a highly promising
approach for image processing [14]. Unlike software, which
requires specific instructions to complete a task, deep learning
allows the system to recognise patterns independently and
make predictions [15].
The deep learning modelling of big data exerts major in-
fluences on modern society, from web searching to financial
technology banking, from facial recognition to medical deci-
sion support [16, 17]. The application of AI will change the
workingmethodologies of many professionals, including phy-
sicians, and this will happen in radiology more quickly than in
other medical fields.
Radiologists, having been pioneers of the digital era in
medicine, can now accept AI as a new partner in their profes-
sion, along with a potential for a higher role of radiology in
healthcare, as we have shown in a previous article [18].
However, there are challenges to AI applications in medicine
and specifically in radiology that depend not on physicians,
but on regulatory institutions and governments [19]. In this
paper we analyse the issues related to recent policy initiatives
to regulate AI in the context of medical device development,
the accountability of AI under the law, and the implications of
data protection and cybersecurity. The main differences be-
tween the policy of the European Union (EU) and that of the
United States (U.S.) will be considered.
Challenges of AI in medicine and radiology
The advancement in algorithm development combined with
the ease of accessing computational resources currently allows
AI applications to be used in medical decision-making tasks
with promising results [14, 17]. The utilization of AI tech-
niques in radiology represents a relevant topic for research
teams. Deep learning algorithms are currently used in mam-
mography for breast cancer detection [20], in CT for colon
cancer diagnosis [21], in chest radiographs for the detection of
pulmonary nodules [22], in MRI for brain tumour segmenta-
tion [23] and for diagnosis of neurologic disorders, such as
Alzheimer disease [24].
The widespread enthusiasm and dynamism regarding the
development of software based on AI in radiology is shown
by the highly positive trend of publications in the literature in
the last 10 years: from 100 to 150 to 700–800 yearly [18].
However, some ethical challenges are straightforward and
need to be guarded against. Notably, one of them is the con-
cern that algorithms may mirror human biases in decision
making. Since healthcare delivery already varies by ethnicity,
it’s possible that some ethnical biases could inadvertently be
built into medical algorithms. AI applications introduced in
nonmedical fields have already been shown to make problem-
atic decisions that reflect biases inherent in the data used to
train them [25]. Recently, a program designed to aid judges in
sentencing by predicting an offender’s risk of recidivism have
shown an unnerving propensity for discrimination [26].
Similarly, an algorithm designed to predict outcomes from
genetic findings may be biased if there are no genetic studies
in certain populations [25].
The intent behind the design of AI also needs to be consid-
ered, because some devices can be programmed to perform in
unethical ways. For example, Uber’s algorithm tool ‘Greyball’
was designed to predict which ride hailers might be undercov-
er law-enforcement officers, thereby allowing the company to
identify and circumvent local laws [25]. Also, Volkswagen’s
algorithm allowed vehicles to pass emissions tests by reducing
their nitrogen oxide emissions when they were being tested
[25]. Analogously, private-sector designers who create AI al-
gorithms for clinical use could be subject to similar tempta-
tions, programming AI systems to guide users toward clinical
actions that would generate increased profits for their pur-
chasers (such as by recommending drugs, tests, or medical
devices in which they hold a stake or by altering referral pat-
terns) but not necessarily reflect better care [25]. These
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examples show the urgency for serious regulations and policy
initiatives about the use of AI, especially in complicated care
practices in which the correct diagnosis of a disease and the
best management of a patient can be controversial.
Regulatory issues and policy initiatives
AI systems do more than process information and assist
officials to make decisions of consequence. Many systems
— such as the software that controls an airplane on auto-
pilot or a fully driverless car — exert direct and physical
control over objects in the human environment [27]. Other
systems, including medical and radiological devices, pro-
vide sensitive services that, when performed by physicians,
require training and certification [15, 19, 27–29]. These
applications raise additional questions concerning the stan-
dards to which AI systems are held and the procedures and
techniques available to ensure those standards are being
met [30]. What about technology under development to-
day, such as autonomous imaging readers, whose very val-
ue turns on bringing skills into an environment where no
one has them? And how do we think about systems that
purport to dispense health advice, which requires adher-
ence to complex fiduciary and other duties pegged to hu-
man judgement [31]?
Since unambiguity is one of the pillars of any legislation
[32], the first aspect policymakers need to address when reg-
ulating any new field is definitions. This aspect becomes an
actual issue with AI, a term that itself contains ambiguities:
what is intelligence? What human abilities are to be consid-
ered the milestones that the AI systems need to accomplish?
The AI’s lack of a stable, unanimous definition or instantiation
complicates efforts to develop an appropriate policy infra-
structure. Moreover, we might question the utility of the word
policy in describing societal efforts to channel AI in the public
interest. There are other terms in circulation. For instance,
governance instead of policy: a new initiative anchored by
the Media Lab of the Massachsetts Institute of Technology
and the Berkman Klein Center for Internet and Society of
the Harvard University refers to itself as the ‘Ethics and
Governance of Artificial Intelligence Fund’ [33]. Anyway,
we need a policy for the governance of AI in medicine (and
radiology).
The second issue for policymakers is whether to consider
AI software used in healthcare as a medical device for
legislave purposes. Both the EU and the U.S. have their own
criteria for identifying healthcare and medical devices, al-
though both definitions share a purpose-based approach.
We will consider below what medical devices are and how
legislation differs in these two geopolitical areas. However, it
is interesting to point out that not all AI programs used in
healthcare will be deemed to bemedical devices. For example,
as Tsang et al. [34] pointed out, Bprograms that analyse large
amounts of data to develop knowledge about a disease or
condition, rather than to decide on treatment options for an
individual patient, may not necessarily be considered as hav-
ing a medical purpose, and hence as a medical device^. It is
the basic distinction between those research programs that
enhance medical knowledge from those that promote changes
in healthcare. How will the latter systems be regulated?
According to Thierer et al. [35] there are two main ap-
proaches that policymakers can use when regulating AI sys-
tems. One is the precautionary principle approach, which im-
poses some limits or sometimes outright bans on certain ap-
plications due to their potential risks. This means that these
applications are never tested because of what could happen in
the worst-case scenarios. The other approach is the so-called
permissionless innovation approach, which allows experi-
mentation to proceed freely, and the issues that do arise are
addressed as they emerge. In 2016, Scherer [36] distinguished,
instead, between ex ante and ex post regulation. Ex ante reg-
ulation is pre-emptive and tries to foresee the risks, similarly to
the precautionary principle [35], while ex post regulation is
retrospective and focuses more on providing a remedy to harm
that actually occurred [37], and it is similar to the
permissionless innovation approach mentioned above [35].
On the one hand, ex post regulation is hindered by
the autonomous nature of AI systems, which evolve and
change constantly according to their experiences and
learning, in an unforeseeable way [38]. On the other
hand, ex ante regulation is obstructed by AI applications
discreetness (their development requires little physical
infrastructure), discreteness (their components can be
designed by different subjects, for different purposes
and without actual coordination), diffuseness (these sub-
jects can be dispersed geographically and yet collaborate
on the same project), and opacity (it can be difficult for
outside observers to identify and understand all the fea-
tures of an AI system) [36].
Finally, a further issue for policymakers is time. Nowadays,
companies understand the potential of machine/deep learning
and are continuously collecting new types of data to analyse
and exploit [39]. In an environment like the technology world
and AI, which changes quickly and unpredictably, regulations
need to be timely to be relevant.
These premises explain why regulation of medical devices
is so controversial and subject to the vagaries of guidelines
and subjective interpretations by the authorities. We consider
below the regulatory minefield and the circumstances in
which a software is regulated as a medical device in the EU
and in the U.S.
Generally, while in the U.S. AI the technology sector pros-
pered in a permissionless innovation policy environment, in
the EU decision-makers adopted a different policy for this
revolutionary technological branch [35]. Certainly, swifter
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approval of AI medical devices helps generate revenue for
manufacturers, and physicians may benefit from having more
tools at their disposal. But the final goal of bringing new
devices to market should be to improve prevention, diagnosis,
treatment, prognosis of diseases with a potential positive im-
pact on patient outcome. Therefore, systems for approving
new medical devices must provide pathways to market for
important innovations while also ensuring that patients are
adequately protected. To achieve these goals, the EU and the
U.S. use different approaches [40].
The EU approach
In the EU, the definition of medical device is provided by
Article 1(2) of Directive 93/42/EEC [41]: the term medical
device is applied to any instrument or other tool, including
any kind of software, intended by the manufacturer to be used
for human beings for the purpose, among others, of diagnosis,
prevention, monitoring, treatment, or alleviation of disease.
This definition has been endorsed by the MEDDEVs, non-
legally binding guidelines drafted by the European
Commission to guide stakeholders in complying with legisla-
tion related to medical devices [42].
The European regulatory regime currently in force flows
from three directives on medical devices [41, 43, 44] and it
requires manufacturers to ensure that the devices they pro-
duce are fit for their intended purpose. This means that
they must comply with a number of essential requirements
set out by the directives themselves. Depending on the risk
classification of the device, whether the essential require-
ments have been met can be assessed either by the manu-
facturer or by a notified body, which is an independent
accredited certification organisation appointed by the com-
petent authorities of EU Member States.
This regulatory framework has been reformed by the new
Medical Devices Regulation (MDR) [45] and the new In Vitro
DiagnosticMedical Device Regulation (IVDR) [46] (Table 1).
Both came into force on 25May 2017, however theMDRwill
apply from 26 May 2020 while the IVDR will apply from 26
May 2022. Because they are regulations, as opposed to
directives, once they apply they do so directly, without the
need for the governments of EU member states to pass legis-
lation to implement their scope [47] (Table 2). This reform
originated from the awareness that the existing directives, cre-
ated in the 1990s [41, 43, 44], are not fit to deal with new,
evolving technologies, including AI systems, and from the
identification of some flaws of this regulatory system, for
example lack of control on notified bodies.
Some of the main characteristics of this reform will be:
extended scope to include a wider range of products, extended
liability in relation to defective products, strengthening of re-
quirements for clinical data and traceability of the devices,
more rigorous monitoring of notified bodies, and improved
transparency through making information relating to medical
devices available to the public [48].
The U.S. approach
In the U.S., regulatory approval allowing machines to do the
work of trained radiologists is a major obstacle still unsolved.
The amount of testing and effort necessary to secure clearance
from the U.S. Food and Drug Administration (FDA) for
allowing machines to provide primary interpretations of im-
aging studies without a radiologist would be overwhelming.
At the end of 2016, the 21st Century Cures Act [49] clar-
ified the scope of FDA regulatory jurisdiction over software
used in healthcare, specifying that a medical device is an in-
strument or other tool Bintended for use in the diagnosis of
disease or other conditions, or in the cure, mitigation, treat-
ment, or prevention of disease, in man or other animals, or
intended to affect the structure or any function of the body of
man or other animals^ [50]. There are some other factors
narrowing the definition, but this is the most important for
the purposes of this paper.
Every AI system falling within this definition will be reg-
ulated by the FDA, as provided by the Federal Food, Drug and
Cosmetic Act [34] (Table 3). The FDA categorises themedical
devices into three classes, according to their uses and risks,
and regulates them accordingly. The higher the risk, the
stricter the control. Class III is the category which includes
the devices involving the greatest risk.
The black box nature and the rapid growth of machine/deep
learning applications will make it difficult for the FDA to
approve in a timely fashion all the new medical devices that
are continuously being developed, given the volume and the
complex nature of testing and verification involved. An ex-
ample was the introduction of computer-assisted detection
software for mammography in 1998 [51], which took many
years and extensive lobbying to obtain clearance from the
FDA to be used as a second screening reader [52].
Table 1 Regulatory framework in the EU on medical devices
Directive 93/42/EEC Directive on medical devices
Will be replaced by MDR on 26 May 2020
MEDDEVS Non-binding guidelines on legislation related to
medical devices
MDR Regulation on medical devices
Applies from 26 May 2020
Repeals Directive 93/42/EEC
IVDR Regulation on in vitro diagnostic medical devices
Applies from 26 May 2022
MDR, Medical Device Regulation; IVDR, In Vitro Diagnostic Medical
Device Regulation; EEC, European Economic Community
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Compared to computer-aided detection systems, FDA
clearance is even harder to be obtained for an AI system that
does not need radiologist’s supervision and cannot be
compared to predicated medical devices used as
replacements for radiologists. For this reason, developers
nowadays present AI systems as aids tools for radiologists
rather than as tools that substitutes for them [53]. This is not
only a legal issue: it implies a relevant discussion about ethical
responsibility, as we will see below.
Data protection and cybersecurity
implications
After the recent ferment about the Cambridge Analytica/
Facebook scandal with personal data misuse [54], an ongoing
debate about balance between privacy and better user experi-
ence (achieved via usage of personal data) is developing, es-
pecially when it comes to sensitive data such as medical in-
formation. The concept of circulating enormous amounts of
confidential information in vast numbers of copies between
many unregulated companies is increasingly insane and risky.
Therefore, in the last decade personal data regulation is in-
creasing and privacy concerns are growing [55].
However, we still need data as an integral part of technol-
ogy development, especially for AI. As we discussed above,
deep learning algorithms require a huge amount of data and
powerful computers, and they usually take a long time to be
trained because of the many parameters under consideration
[19, 28]. The lack of well-annotated big datasets for training
AI algorithms is a key obstacle to a large introduction of these
systems in radiology [3, 13, 56]. Access to big data of medical
images is needed to provide training material to AI devices, so
that they can learn to recognise imaging abnormalities [13,
57]. One of the problems is that sensitive data might either
be harvested illicitly or collected from unknown sources [58]
because of the lack of unique and clear regulations [59].
In the era of electronic medical records, AI complicates an
already complex cybersecurity landscape [60]: the concept of
confidentiality requires that a physician withholds information
from the medical record in order to keep it truly confidential
[25]. Once a clinical decision based on AI is integrated into
clinical care, withholding information from electronic records
will become increasingly difficult, since patients whose data
are not recorded cannot benefit from AI analyses [25]. The
implementation of deep learning systems will therefore re-
quire a reimagining of confidentiality and other core tenets
of medical ethics. Before using government over-regulation,
we need to face the data protection and cybersecurity impli-
cations technologically. Data protection can no longer rely on
current technologies that allow spreading of personal data and
require data sharing at a large and uncontrolled scale [61].
In radiology, and in medicine in general, AI medical de-
vices should use deep learning to provide data about patients
without requiring their personally identifiable information in
exchange. Currently, the use of AI raises two issues relating to
the data collected by the devices. On the one hand, data must
be protected from the same bodies collecting them. On the
other hand, the same data are threatened by cyberattacks to
these bodies as well as to the devices themselves.
Data protection in the EU
Because of these threats, European regulators have decided to
update the legislation concerning data protection and cyberse-
curity (Table 4). The General Data Protection Regulation
(GDPR) applies from 24 May 2018, substituting the
European legal framework for data protection as set out by
Directive 95/46/EC [62]. According to the GDPR, all data
processing and use should be opt-in, and consumer consent
Table 2 Main differences
between Directives and
Regulations
Directives ≠ Regulations
The directives set out the objectives that must be
attained. Once they are in force, EU member
states have a limited period of time to implement
national legislation that will satisfy those
objectives.
Regulations are applied directly in EU Member
States, without the need for national legislation to
implement their purposes. Once they are in force,
member states must comply with them.
EU European Union
Table 3 Regulatory framework in the USA on medical devices
• 21st Century Cures Act [ref. 49] 
• Federal Food, Drug and Cosmec Act  [ref. 34] FDA
FDA Food and Drug Administration
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for data use should be clear. In general, the GDPR completely
prohibits current data marketing based on third-party non
opt-in personal data. The GDPR is a more suitable instrument
to regulate AI because it has an extended territorial scope and
wider rights for data subjects. For instance, enhanced notifi-
cation requirements (under Article 33, personal data breaches
must be notified to the supervising authority within 72 h), and
rights to compensation for material or non-material damage
and additional liability for data controllers and processors
(Article 88):1 [63].
Again, because it is a regulation, the GDPR applies direct-
ly, and institutions have to comply with it starting from 24
May 2018 (which is why 2 years have been allowed for im-
plementation since its enforcement on 24 May 2016).
In addition, the EU adopted the Cybersecurity Directive
[64], which had to be implemented by the member states by
10 May 2018. This sets out a number of requirements for EU
member states which aim to prevent cyberattacks and keep
their consequences under control. Among other things, mem-
ber states are required to ensure that operators of essential
services take appropriate measures to prevent and minimise
the impact of incidents and to preserve service continuity
(Articles 14(2) and 16(2)), and to ensure that supervisory au-
thorities are notified of incidents without undue delay
(Articles 14(3) and 16(3)) [64].
Data protection in the U.S.
While in the U.S. government regulation is less strict, cases
like Cambridge Analytica/Facebook should remind the gov-
ernment that actions should be taken, and that the behaviour of
companies needs changes.
The Health Insurance Portability and Accountability Act
(HIPAA) is a compliance focus for health information concerns
[34]. This act elaborates rules requiring, among other things,
the formulation of policies and the setup of training systems for
those who have access to sensitive data [34] (Table 5).
Moreover, HIPAA does not hinder the action of individual
states, where it protects further the individual’s right to privacy.
Cybersecurity is dealt with by the FDA, which requires
manufacturers to report only a limited number of risks their
devices present and actions taken to minimise the vulnerabil-
ity [34] (Table 5). The black box features of deep learning and
the lack of transparency regarding how results are obtained
have thorny legal implications [58]. In some cases, even the
designers do not completely understand how AI algorithms
process the data [58], so that the lack of transparency is, ba-
sically, a lack of knowledge. Considering the current amount
of data collected, and that with an increased presence of AI
applications this can only grow, regulatory actions regarding
cybersecurity will face continuous challenges.
Accountability and responsibility: an “internal
evidence” from AI in the frame
of evidence-based medicine?
Alongside the actual regulation and data protection, there are
other legal implications of AI and its use, whether in
healthcare or elsewhere. One of these is accountability. As
soon as AI starts making autonomous decisions about diagno-
ses and treatments, moving beyond its role asmerely a support
tool, a problem arises as to whether its developer can be held
accountable for its decisions. The first question is: who will be
sued if an AI-based device makes a mistake?
Errors in AI appear mainly when confounding factors are
correlated with pathologic entities in the training datasets rather
than actual signs of disease. When AI devices decide, their
decision is based on the collected data, the algorithms they
are based on, and what they learnt since their creation. The
reason their decisions are unpredictable is twofold [36]. On
the one hand,AI devices, even if they mimic human brain neural
networks, think differently than humans. Better, they think
more quickly and accurately [38, 56, 58]. There is a huge num-
ber of possibilities in every given situation, and humans are
unable to process all of these and consider them in order to
make a decision. We consider only what is more obvious for
our brains, while AI systems can consider every potential sce-
nario and every consideration [2, 3, 15, 29, 39, 56, 65]. Because
of this, where faced with a decision to make, we do not share a
common basis with AI devices. Therefore, we are unable to
predict what they will decide in a given set of circumstances.
On the other hand, AI systems are designed to learn from their
genuine experiences, and these are by their very nature unpre-
dictable. Because it is not possible to foresee what experiences a
system will encounter, neither is it possible to foresee how the
system will develop. For these reasons, it is worth considering,
when something ‘goes wrong’ following a decision made by an
AI application, whether the device itself or its designer/builder
1 Data controllers are people who determine the purposes for which and the
way any personal data are processed, while a data processor is the person
who actually processes the data for a data controller.
Table 4 Regulatory framework in the EU on data protection
Directive 95/46/EC Directive on data protection
Has been replaced by the GDPR
GDPR Regulation on data protection
Applies from 24 May 2018
Replaces Directive 95/46/EC
Directive (EU) 2016/1148 Directive on cybersecurity
Applies from 10 May 2018
EC, European Community; GDPR, General Data Protection Regulation;
EU, European Union
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is to be considered at fault. Will the designer be deemed negli-
gent for not having foreseen what we have described as unfore-
seeable? Or for having left the possibility for development of
the AI-device that would bring it to that decision?
AIwill play an increasingly important part over the next years
in the relationship between doctors and patients [15, 19, 35, 53,
66] and it will need to be bound by core ethical principles, such
as beneficence and respect for patients, which have guided cli-
nicians during the history of medicine [25]. We should remem-
ber, indeed, that the radiologist, as a physician, is much more
than simply an interpreter of images. The duties of a practicing
radiologist also include communication of findings, quality as-
surance, quality improvement, education, interventional radiolo-
gy procedures, policy-making, and many more tasks that cannot
be performed by computer programs [2]. The ability to provide a
nuanced interpretation for complex findings,medical judgement,
and wisdom of an experienced radiologist is difficult to quantify
and even more difficult to simulate with AI systems [15].
Given the evolving complexity of AI technology, it is al-
most inevitable that some of its inner workings will appear to
be a ‘black box’ to all but the very few who can comprehend
how they work [58]. But that does not mean accountability is
out of the question.
Importantly, in a broader theoretical framework, we should
distinguish between data analysis (in this case, the AI-device
output) and decision making. In the context of evidence-based
medicine [67], the best external evidence (data from high-
quality studies and meta-analysis, guidelines from governmen-
tal bodies and medical societies) has to be combined with pa-
tients’ preferences and values by using our personal medical/
radiological expertise. We could say that, introducing AI in
radiology, we have also a kind of internal evidence coming
from the application of AI to the patients’ imaging procedure(s).
One can argue that AI might, at least in the future, be able to do
this job instead of physicians. However, when patients’ prefer-
ences and values play a non-negligible role (and hopefully this
factor will not reduce its weight in the future), human interac-
tion and empathy by a physician/radiologist and a patient re-
main a fundamental dimension. Indeed, AI will allow radiolo-
gists to have more time to communicate with patients and to
confer with colleagues in multidisciplinary teams, as they will
be less busy doing routine and monotonous tasks that can be
effectively performed by computers [53].
Accountability for an AI output may be also a simple mat-
ter for insurance purposes. Ethical and legal responsibility for
decision making will remain in the hand (better, in the mind)
of the natural intelligence of physicians. From this viewpoint,
it’s probable that multidisciplinary boards will take the respon-
sibility in difficult cases, considering the information AI pro-
vides as relevant but not always conclusive.
Conclusions
While the application of AI in medicine and radiology has
several challenges to face, we should accept the fact that we
need it. We need all these technologies and devices that rely on
sensitive data to improve patient care and treatment. We believe
that challenges such as the new policy initiatives, the regulation
of data protection and cybersecurity, the debate about the un-
usual accountability and responsibility issues, the questions
about the fiduciary relationship between patients and AI med-
ical systems will have to be addressed as soon as possible.
AI-based devices could be built to reflect the ethical stan-
dards that have guided other actors in healthcare and could be
held to those standards. A key step will be determining how to
ensure that they are, whether by means of combination of
policy enactment and programming approaches.
A good application of AI may be powerful, helpful, and
valuable. On the contrary, a bad or unethical use of this
cutting-edge technology may be dangerous, and patients, phy-
sicians (radiologists), and regulatory authorities must work
together to prevent this [57]. In a spirit of good cooperation,
we must find a balance that provides security, privacy protec-
tion, and ethical use of sensitive information to ensure both
humane and regulated (and, therefore, responsible) manage-
ment of the patients.
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